



## Treatment of liver fibrosis: Clinical aspects

Submitted by Emmanuel Lemoine on Fri, 07/18/2014 - 09:40

Titre	Treatment of liver fibrosis: Clinical aspects
Type de publication	Article de revue
Auteur	Calès, Paul [1], Boursier, Jérôme [2], Chaigneau, Julien [3], Oberti, Frédéric [4], Rousselet, Marie-Christine [5]
Editeur	Elsevier Masson
Type	Article scientifique dans une revue à comité de lecture
Année	2009
Langue	Anglais
Date	2009/10
Numéro	10-11
Pagination	958 - 966
Volume	33
Titre de la revue	Gastroentérologie Clinique et Biologique
ISSN	0399-8320
Résumé en anglais	<p>Summary</p> <p>The main objective of antifibrotic treatment is to avoid the complications of chronic liver disease where its cause cannot be treated. Three main therapeutic endpoints can be targeted: cause; comorbidity; and fibrosis. Antifibrotic treatment is any intervention independent of cause that is intended to modify the course and/or level of fibrosis through direct action on the mechanisms of fibrosis. Several modalities are here considered: reduction of fibrosis course; reversion of fibrosis; and reversion of cirrhosis. Semiquantitative histological staging and morphometry are complementary techniques for monitoring fibrosis. The degree of fibrosis should preferentially be estimated by fibrosis progression based on measurements taken at baseline and during treatment, rather than by raw static measurements. Surrogate markers are the only tools for assessing drug efficacy in clinical practice, and are especially useful for checking compliance and identifying poor or non-responders. We propose to define non-response as no decrease in fibrosis progression. The renin-angiotensin system is a good candidate target for antifibrotic treatment, and angiotensin-II type-1 receptor blockers, such as sartans, are probably effective. Clinical trials are currently ongoing using marketed drugs, while new multitargeted drugs are likely to emerge from basic research.</p>
URL de la notice	<a href="http://okina.univ-angers.fr/publications/ua3498">http://okina.univ-angers.fr/publications/ua3498</a> [6]
DOI	10.1016/j.gcb.2009.07.020 [7]
Lien vers le document	<a href="http://dx.doi.org/10.1016/j.gcb.2009.07.020">http://dx.doi.org/10.1016/j.gcb.2009.07.020</a> [7]

### Liens

- [1] <http://okina.univ-angers.fr/p.cales/publications>
- [2] <http://okina.univ-angers.fr/jerome.boursier/publications>

- [3] <http://okina.univ-angers.fr/j.chaigneau/publications>
- [4] <http://okina.univ-angers.fr/f.oberti/publications>
- [5] <http://okina.univ-angers.fr/m.rous/publications>
- [6] <http://okina.univ-angers.fr/publications/ua3498>
- [7] <http://dx.doi.org/10.1016/j.gcb.2009.07.020>

Publié sur *Okina* (<http://okina.univ-angers.fr>)